07:00 , Oct 6, 2014 |  BioCentury  |  Finance

3Q14 Stock Wrap-Up: Going big again

For the second quarter in a row, only the large caps finished in the black in 3Q14. In the over $5 billion segment, which was up 9%, gainers outnumbered decliners 22-9, while the decliners led...
07:00 , Sep 1, 2014 |  BC Week In Review  |  Clinical News

Auriclosene: Development discontinued

NovaBay discontinued development of an ophthalmic formulation of auriclosene to treat adenoviral conjunctivitis after the product given for 10 days missed the primary and secondary endpoints vs. vehicle in the double-blind, international Phase IIb BAYnovation...
07:00 , Sep 1, 2014 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Alkermes plc (NASDAQ:ALKS) gained $1.49 to $44.73 last week after submitting an NDA to FDA for aripiprazole lauroxil to treat schizophrenia. The product is a once-monthly, injectable formulation of aripiprazole that uses Alkermes' LinkeRx technology....
00:35 , Aug 21, 2014 |  BC Extra  |  Clinical News

NovaBay falls after dropping auriclosene for conjunctivitis

NovaBay Pharmaceuticals Inc. (NYSE-M:NBY) was off $0.44 (35%) to $0.81 on Wednesday after discontinuing development of an ophthalmic formulation of auriclosene ( NVC-422 ) to treat adenoviral conjunctivitis. The decision came after the product missed...
07:00 , Jun 9, 2014 |  BC Week In Review  |  Clinical News

Auriclosene: Completed Phase IIb enrollment

NovaBay completed enrollment of about 450 patients in the double-blind, placebo-controlled, international Phase IIb BAYnovation trial evaluating auriclosene ophthalmic solution for 10 days. NovaBay plans to start a Phase II trial of auriclosene to reduce...
08:00 , Jan 6, 2014 |  BioCentury  |  Finance

4Q Stock Wrap-Up: All's well that ends well

Although two segments lost ground in 4Q13, all of biotech's market cap groups finished 2013 in the black. Large caps valued at more than $5 billion led the way in the fourth quarter, tacking on...
08:00 , Dec 23, 2013 |  BC Week In Review  |  Clinical News

Auriclosene: Phase IIb start

Next year, NovaBay said it will begin evaluating an optimized formulation of auriclosene to treat patients with impetigo. In November, NovaBay reported that a topical gel formulation of auriclosene missed the primary endpoint (see BioCentury,...
08:00 , Nov 11, 2013 |  BC Week In Review  |  Clinical News

Auriclosene: Phase IIb data

A Phase IIb trial in patients with impetigo showed that a topical gel formulation of auriclosene missed the primary endpoint. Auriclosene was well tolerated. NovaBay and partner Galderma could not be reached for details, but...
08:00 , Nov 11, 2013 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones Aeterna Zentaris Inc. (TSX:AEZ; NASDAQ:AEZS) was up C$0.01 to C$1.42 and unchanged at $1.35 on NASDAQ last week after submitting an NDA to FDA for Solorel macimorelin ( AEZS-130 ) to diagnose adult...
01:36 , Nov 7, 2013 |  BC Extra  |  Clinical News

NovaBay falls on impetigo miss

NovaBay Pharmaceuticals Inc. (NYSE-M:NBY) said a topical gel formulation of the company's auriclosene ( NVC-422 ) missed the primary endpoint in a Phase IIb trial to treat impetigo. NovaBay and partner Galderma S.A. (Lausanne, Switzerland)...